IP Seminar - AI-Driven Medical Innovation: IP Strategy and Commercialization

10:00am - 11:00am
5/F InnoBay, Martin Ka Shing Lee Innovation Building

Supporting the below United Nations Sustainable Development Goals:支持以下聯合國可持續發展目標:支持以下联合国可持续发展目标:

This session covers the IP and data strategy issues that universities and spinouts need to get right to commercialize and license their AI-driven life sciences and medical technologies and data. The principles apply in any jurisdiction: establishing clear ownership among the university, inventors and collaborators; how to patent AI in medicine, including inventorship when AI is part of the research and filing before publication; deciding what to patent and what to keep as a trade secret; and securing the data rights and consent terms needed to license clinical and research data, including for AI model training.

The session closes with an add on for those commercializing in the US, the largest market for AI health products, covering FDA pathways for AI medical software, how US approval compares with Europe, China and Hong Kong, and why reimbursement is a separate hurdle that decides whether a cleared product actually gets bought.
 

講者/ 表演者:
Mr. Roger Kuan
Partner, Norton Rose Fulbright US LLP

Roger Kuan leads the U.S. Digital Health and Precision Medicine Practice at Norton Rose Fulbright, advising digital health companies and research institutions on intellectual property (IP), data rights, and regulatory compliance.

His expertise covers comprehensive IP strategy and portfolio management, including patents, trademarks, copyrights, and trade dress. He also provides strategic counsel on data rights, licensing, freedom-to-operate analyses, monetization, dispute resolution, and IP due diligence. Roger focuses on the life sciences sector, assisting clients with research tools, diagnostics, medical devices, analytical software, digital therapeutics, and biomanufacturing platforms.

Roger specializes in emerging technologies, including precision medicine (genomic sequencing, AI/ML, computational genomics, molecular diagnostics, companion diagnostics), digital health solutions (mobile apps, clinical decision support, imaging diagnostics, wearables, software), and 3D printing/bioprinting.

Before joining Norton Rose Fulbright, Roger was Director and IP Counsel at Thermo Fisher Scientific, leading global IP strategy for molecular diagnostics, bioproduction, nucleic acid sequencing, and life sciences tools. 

Roger was recognized by Lawdragon in 2025 as one of the "500 Leading Global IP Lawyers." He has been recommended by the Legal 500 for intellectual property in 2019, 2024, and 2025, and was named a leading IP lawyer by IAM Patent 1000 in 2024 and 2025.

語言
英文
適合對象
校友
教職員
研究生
本科生
主辦單位
Office of Knowledge Transfer
報名方法
新增活動
請各校內團體將活動發布至大學活動日曆。